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ABSTRACT
Proteasome inhibitors have distinct properties and the biochemical consequences
of suppressing ubiquitin E1 enzymes and the proteasome differ. We compared the
effects of the proteasome inhibitors bortezomib, ixazomib and carfilzomib and the
ubiquitin E1 enzyme inhibitor MLN7243/TAK-243 on cell viability and cell death in
normal keratinocytes and cutaneous squamous cell carcinoma (cSCC) cell lines. The
effects of both a pulse of treatment and more extended incubation were investigated.
This is relevant to directly-delivered therapy (topical treatment/intratumoral
injection) where the time of exposure can be controlled and a short exposure may
better reflect systemically-delivered inhibitor pharmacokinetics. These agents can
selectively kill cSCC cells but there are variations in the pattern of cSCC cell line
sensitivity/resistance. Variations in the responses to proteasome inhibitors are
associated with differences in the specificity of the inhibitors for the three proteolytic
activities of the proteasome. There is greater selectivity for killing cSCC cells
compared to normal keratinocytes with a pulse of proteasome inhibitor treatment than
with a more extended exposure. We provide evidence that c-MYC-dependent NOXA
upregulation confers susceptibility to a short incubation with proteasome inhibitors
by priming cSCC cells for rapid BAK-dependent death. We observed that bortezomibresistant cSCC cells can be sensitive to MLN7243-induced death. Low expression of
the ubiquitin E1 UBA1/UBE1 participates in conferring susceptibility to MLN7243
by increasing sensitivity to MLN7243-mediated attenuation of ubiquitination. This
study supports further investigation of the potential of proteasome and ubiquitin
E1 inhibition for cSCC therapy. Direct delivery of inhibitors could facilitate adequate
exposure of skin cancers.
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INTRODUCTION

of these compounds inhibit the chymotrypsin-like activity
of the proteasome. Bortezomib and ixazomib inhibit the
caspase-like activity at moderately high concentrations
and the trypsin-like activity at high concentrations [17].
Moderately high concentrations of carfilzomib inhibit
both the caspase and trypsin-like activities [18, 19]. In
cells the half-life for recovery of the chymotrypsin-like
activity of the proteasome after inhibitor removal is less
than 4 hours for ixazomib, 15 to 20 hours for bortezomib
and can be less than 24 hours for carfilzomib [18-21].
Following intravenous injection proteasome inhibitors
reach μM levels in plasma but the concentration declines
within hours [22-24]. Binding to proteasomes in patient
tissues could contribute to this reduction in levels [25].
There is a secondary slower phase of elimination and low
plasma concentrations of proteasome inhibitors can be
maintained for several days. Effective systemic treatment
is required for distant cSCC metastasis [26]. There are
ongoing clinical trials in other cancers, including trials
involving the more recently developed inhibitors, but to
date the response of solid tumours in general to systemic
proteasome inhibitor therapy has been poor [23, 27]. This
may be related to difficulties in achieving a sufficient
extent or duration of proteasome inhibition in solid
tumours by systemic delivery [16, 28]. However, there is
great potential for treating skin cancer including cSCC by
topical therapy or intratumoral injection. With directlydelivered therapy the inhibitor dose and the duration of
inhibitor exposure could be controlled to achieve optimum
tumour selectivity [28-31]. Patients with inoperable locoregional disease would benefit from effective directlydelivered drug therapy [32-34]. It would also be useful
in neoadjuvant and adjuvant settings to reduce the
impact of surgery and to prevent local tumour recurrence
[32, 35, 36].
An alternative way of targeting the core ubiquitinproteasome system is to inhibit the ubiquitin E1 enzymes
[37]. Blocking ubiquitin conjugation by suppressing
ubiquitin E1s has the potential to attenuate all cellular
events that are controlled by ubiquitination not simply
proteasomal degradation. Substrate ubiquitination can
however be differentially dependent on the level of E1
activity [13, 38]. The cellular pathways affected may
consequently be determined by the extent of E1 inhibition.
MLN7243/TAK-243 is a recently developed high-affinity
inhibitor with selectivity for ubiquitin E1s over other UBL
protein E1s [39-42]. We confirm in this report that it can
suppress both UBA1 and UBA6. MLN7243 is the first
ubiquitin E1 inhibitor to enter a clinical trial for cancer
therapy (NCT02045095). It has been observed that in
mice systemically treated with MLN7243 plasma levels
decline rapidly but the inhibitor has a long half-life in
tumours [39].
The therapeutic potential for cSCC of targeting the
ubiquitin-proteasome system has not been adequately
explored. Furthermore, the anti-tumour activity and the

Cutaneous squamous cell carcinoma (cSCC)
causes significant mortality and morbidity in the general
population [1]. In addition, cSCC has a huge impact on
patients with the chronic skin blistering disease recessive
dystrophic epidermolysis bullosa (RDEB) [2]. The
cumulative risk of death from cSCC in patients with
severe generalized RDEB is 80% by the age of 55 [3].
Immunosuppressed patients are also at high risk of cSCC.
For example, organ transplant recipients are up to 150-fold
more likely to develop cSCC than the general population
and these tumours tend to be more aggressive [4]. cSCC
is responsible for 25% of deaths due to skin cancer in the
United Kingdom and in some regions of the United States
it is responsible for more deaths than melanoma [1]. Most
cSCCs can be successfully treated by surgery. However,
there is a need for improved therapy for the minority of
cSCCs that are responsible for this substantial health
burden [5].
Ubiquitination regulates protein stability, activity,
association and localization [6, 7]. This is important in
many fundamental processes and pathways of relevance
to tumorigenesis and cancer therapy. Ubiquitination
of target proteins involves three classes of enzymes.
Ubiquitin is loaded onto ubiquitin conjugating enzymes
(E2s) by ubiquitin activating enzymes (E1s). Ubiquitin
ligases (E3s) facilitate transfer of ubiquitin from E2s
to substrates [8, 9]. There are two ubiquitin E1s in the
human genome: UBA1/UBE1 and UBA6 [10-12]. These
E1s pass ubiquitin onto overlapping but distinct groups of
E2s [11, 13]. UBA1 is thought to be involved in ubiquitin
conjugation to the majority of cellular substrates [11].
However, UBA6 is required for the ubiquitination of a
subset of proteins [13]. UBA6 is also the E1 responsible
for activation of the ubiquitin-like (UBL) protein
FAT10 [10, 14]. Ubiquitination can target proteins for
proteasomal degradation. The proteasome is formed from
two multi-subunit protein complexes: the 20S core and the
19S regulatory particle. It has three proteolytic activities
which are conferred by different subunits in its 20S core:
PSMB6/β1 (caspase-like), PSMB7/β2 (trypsin-like) and
PSMB5/β5 (chymotrypsin-like). Protein degradation is
differentially dependent on these proteolytic activities
[15, 16]. The chymotrypsin-like activity plays a major
role in protein degradation but the other activities of the
proteasome make an additional contribution.
The proteasome inhibitor bortezomib has been
widely used to treat patients with multiple myeloma. Two
additional proteasome inhibitors: ixazomib and carfilzomib
have recently been approved for multiple myeloma
therapy. These agents differ in their affinity for inhibition
of the individual proteolytic activities of the proteasome
and/or in their reversibility. The importance of these
differences in influencing the therapeutic efficacy of these
inhibitors is not fully understood. At low concentrations all
www.oncotarget.com
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degree of tumour selectivity of proteasome and ubiquitin
E1 inhibition have not been compared for any cancer type.
It is common in pre-clinical investigations to determine
the effect of extended exposure to proteasome inhibitors
on the viability of cultured cells. It is relevant for directlydelivered therapy to assess the effects of different times of
tumour treatment. It may also better model systemicallydelivered inhibitor pharmacokinetics to investigate the
consequences of a shorter pulse of inhibitor treatment
[21-24, 39]. Multiple pathways have been implicated
in killing cells in response to continuous proteasome
inhibitor exposure [43]. Much remains to be learned
about the dominant mechanisms underlying sensitivity to a
pulse of proteasome inhibition. In addition, little is known
regarding the determinants of sensitivity to ubiquitin E1

suppression. In this study we compared the effects on cell
viability and cell death of long and short exposure to the
three clinically approved proteasome inhibitors and the
ubiquitin E1 inhibitor MLN7243. This was done in normal
keratinocytes and in cSCC cell lines derived from RDEB,
immunocompetent and immunosuppressed patients.
These agents can selectively kill cSCC cells originating
from primary and metastatic tumours. There is greater
selectivity for cSCC compared to normal keratinocytes
with a pulse of proteasome inhibitor exposure than with
a more extended treatment. There are differences between
inhibitors in the magnitude of the window of tumour
selectivity and in the pattern of sensitivity of cSCC cell
lines. Mechanisms contributing to these differences were
identified.

Figure 1: cSCC cell lines can be highly sensitive to a pulse of bortezomib. (A-C) Cells were continuously incubated with

the proteasome inhibitor bortezomib for 72 hours (Continuous) or treated with bortezomib for 8 hours and then maintained in drug-free
medium for a further 64 hours (Pulse). Cell viability (live cell number) expressed as a percentage of carrier alone and the percentage of
dead cells were assayed by real-time imaging. Values are the mean -/+ SEM of 3 independent experiments. (A) Normal keratinocytes from
an RDEB patient (RDEBK) and cSCC cell lines derived from primary tumours from RDEB patients (SCCRDEB 2, 3 and 4) and from an
RDEB cSCC metastasis (SCCRDEBMet). (B) Normal human keratinocytes (NHK) and cSCC lines derived from paired primary tumours
and metastases from immunocompetent (SCCIC1 and SCCIC1Met) and transplant patients (SCCT and SCCTMet). (C) Relative EC50
values (μM) for reducing cell viability (live cell number) and for promoting cell death. There was little cSCC selectivity with continuous
exposure to bortezomib but the majority of cSCC cell lines were more sensitive to a pulse of bortezomib than normal keratinocytes. (D)
The three proteolytic activities of the proteasome were assayed 8 hours after the addition of bortezomib. The results were expressed as
a percentage of the activity with carrier alone. Values are the mean -/+ SEM of 3 independent experiments. The cSCC cells lines most
sensitive to pulse of bortezomib were killed at bortezomib concentrations that strongly inhibit both the chymotrypsin and caspase-like
activities of the proteasome.
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RESULTS

The general pattern of ixazomib susceptibility in
normal keratinocytes and representative cSCC cell lines
was similar to that of bortezomib (Supplementary Figure
3). Under the conditions used the reduction in viability
and the level of death observed in bortezomib/ixazomibsensitive SCCRDEB4 cells with a short exposure to low
concentrations of ixazomib was less than that with a
pulse of bortezomib (Supplementary Figure 3 and Figure
1). This may be related to the faster dissociation rate of
ixazomib as the specificity of bortezomib and ixazomib
for the proteolytic activities of the proteasome are very
similar (Figure 1D and Supplementary Figure 3D) [18-21].
Carfilzomib was more generally selective for killing
cSCC cells compared to normal keratinocytes than the
other agents tested (Figure 2). The cSCC selectivity was
greater with continuous exposure to carfilzomib than
with continuous exposure to bortezomib. Under these
conditions the EC50 values for killing cSCC cells were
3 to 14-fold lower than for NHK with carfilzomib and a
maximum of 2.5-fold lower with bortezomib (Figure 1 and
2). RDEB cSCC cell lines were particularly susceptible to
death induced by continuous treatment with carfilzomib. A
pulse of carfilzomib exposure resulted in further increases
in cSCC selectivity and all cSCC cell lines were killed
at substantially lower concentrations of carfilzomib than
normal keratinocytes. With a short carfilzomib exposure
the EC50 values for killing cSCC cells were 4.5 to 30-fold
lower than for NHK.
The ubiquitin E1 inhibitor MLN7243 selectively
killed a subset of cSCC lines (Figure 3). SCCT and
SCCRDEBMet cells were the most susceptible to
continuous treatment with MLN7243. SCCIC1Met cells
were also selectively killed by an extended exposure to
this agent. Death in SCCRDEBMet cells displayed the
greatest sensitivity to a pulse of MLN7243. There were
striking differences between responses to this inhibitor
and bortezomib: MLN7243-sensitive SCCRDEBMet and
SCCIC1Met cells were the most resistant to bortezomib
(Figure 1 and 3). Conversely, SCCIC1 cells were
susceptible to a pulse of bortezomib but were highly
resistant to ubiquitin E1 inhibition.
These results indicate that a good window of
selectivity can be achieved with the inhibitors for the
killing of cSCC cells derived from primary and metastatic
tumours compared to normal keratinocytes but that there
are differences in the pattern of inhibitor sensitivity.
Clonogenic assays confirmed variations in inhibitor
sensitivity observed in the shorter-term real-time imaging
assays (Figure 4).
The proteolytic activities of the proteasome
were assayed at the end of an 8-hour treatment with
proteasome inhibitors, which corresponds to the length
of the pulse used for viability/cytotoxicity assays (Figure
1D and 2D and Supplementary Figure 3D). At low doses
carfilzomib is more specific for the chymotrypsin-like
activity than bortezomib and ixazomib which could

Comparison of the anti-cSCC activity of
proteasome and ubiquitin E1 inhibitors
We investigated whether there were differences
in responses to the proteasome inhibitors bortezomib,
ixazomib and carfilzomib and the ubiquitin E1 inhibitor
MLN7243. The effects of these agents were assessed
in untransformed normal keratinocytes from an RDEB
patient (RDEBK), normal human keratinocytes (NHK)
and eight cSCC-derived cell lines. cSCCs arise from
the malignant transformation of keratinocytes in the
epidermis. Keratinocytes constitute over 90% of cells
within this layer of the skin. It is consequently appropriate
to include keratinocytes in the study as the cell of
cSCC origin and a major normal cell type that would
be exposed to locally-delivered therapy. Measurement
of the proteolytic activities of the proteasome verified
target suppression by proteasome inhibitors (Figure 1D
and 2D and Supplementary Figure 3D). In addition, we
confirmed that MLN7243 can reduce the cellular level of
ubiquitin conjugates (Figure 3D). As part of the catalytic
mechanism E1 and E2 enzymes form reducing agentsensitive thioesters with ubiquitin and UBL proteins [41,
44]. MLN7243 decreased UBA1 and UBA6 thioesters
and thioesters of the UBA6 specific E2 UBE2Z/USE1
(Supplementary Figure 1 and Figure 7). This confirms that
both UBA1 and UBA6 are inhibited by MLN7243.
Clonogenic assays indicated that a 6 to 8-hour
treatment with the inhibitors was required for efficient
anti-cSCC activity (Supplementary Figure 2). To compare
extended and short exposures cells were continuously
incubated with inhibitors for 72 hours or treated with
an 8-hour pulse of these agents and then maintained in
drug-free culture for a further 64 hours. Cell viability (live
cell number) and cell death were assayed by real-time
imaging. Cell viability was generally reduced at a lower
concentration of the agents than required to promote cell
death (Figure 1 to 3 and Supplementary Figure 3). This
reflects greater inhibitor sensitivity of proliferation.
With continuous exposure to bortezomib there was
little selectivity for cSCC compared to untransformed
keratinocytes (Figure 1). However, the majority of cSCC
cell lines were more sensitive to a pulse of bortezomib
than normal keratinocytes. Indeed, a larger window of
selectivity for killing sensitive cSCC cells was observed
with a pulse of bortezomib than with exposure to
carfilzomib or MLN7243 (Figure 1 to 3). The maximum
difference in EC50 for killing cSCC cells compared to
NHK was 110, 30 and 7.5-fold for bortezomib, carfilzomib
and MLN7243 respectively. Furthermore, in half of the
cSCC cell lines the EC50 for bortezomib-induced cell
death was at least 30-fold lower than for NHK. However,
death in SCCRDEBMet and SCCIC1Met cells was
insensitive to a short bortezomib exposure.
www.oncotarget.com
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underlie the greater cSCC selectivity of continuous
carfilzomib exposure (Figure 1 and 2 and Supplementary
Figure 3). Bortezomib and ixazomib had similar effects
on the proteolytic activities of the proteasome (Figure
1D and Supplementary Figure 3D). Death resulting from
a pulse of bortezomib or ixazomib exposure in the most
sensitive cSCC cells occurred at inhibitor concentrations
that profoundly inhibit both the chymotrypsin and
caspase-like activities while having a relatively
modest effect on the trypsin-like activity (Figure 1 and
Supplementary Figure 3). Killing of normal keratinocytes
and resistant cSCC cells was linked with further
inhibition of the trypsin-like activity at high inhibitor
concentrations. Death in cSCC cells exposed to a pulse
of carfilzomib was associated with strong inhibition of
the chymotrypsin-like activity and moderate inhibition

of both the caspase and trypsin-like activities (Figure 2).
Carfilzomib-dependent death in normal keratinocytes
was linked with progressive inhibition of the residual
activities. A pulse of proteasome inhibitor treatment that
specifically blocked the chymotrypsin-like activity of the
proteasome caused little or no death in cSCC cell lines.
This is consistent with observations in myeloma and
breast cancer cells [16, 21]. These results indicate that
the level of cSCC selectivity of a pulse of proteasome
inhibitor treatment is influenced by the differential
dependency for survival in sensitive tumour cells and
normal keratinocytes on the proteolytic activities of the
proteasome. Differences in the profile of inhibition of the
proteolytic activities of the proteasome could contribute
to the observed variations in cSCC susceptibility to
bortezomib/ixazomib and carfilzomib.

Figure 2: Carfilzomib exhibits more general anti-cSCC selectivity than bortezomib. (A-C) Cells were continuously incubated

with the proteasome inhibitor carfilzomib or treated with an 8-hour carfilzomib pulse. Cell viability (live cell number), expressed as a
percentage of carrier alone and the percentage of dead cells were assayed by real-time imaging 72 hours after drug addition. Values are the
mean -/+ SEM of 3 independent experiments. (A) Normal keratinocytes and cSCC cell lines from RDEB patients. (B) Normal keratinocytes
and cSCC cell lines from: immunocompetent (SCCIC) and transplant (SCCT) patients. (C) Relative EC50 values (μM) for reducing cell
viability (live cell number) and for promoting cell death. cSCC cell lines were more sensitive to continuous carfilzomib treatment and a
pulse of carfilzomib exposure than normal keratinocytes. (D) The proteolytic activities of the proteasome were assayed 8 hours after the
addition of carfilzomib. The results were expressed as a percentage of the activity with carrier alone. Values are the mean -/+ the range of
2 independent experiments. Cell death in RDEB cSCC cell lines in response to continuous exposure to carfilzomib occurred at carfilzomib
concentrations where only the chymotrypsin-like activity was inhibited. Death of cSCC cells induced by a short pulse of carfilzomib was
associated with robust inhibition of the chymotrypsin-like activity and moderate inhibition of both the caspase and trypsin-like activities.
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c-MYC, NOXA and BAK participate in killing
cSCC cells in response to a pulse of treatment
with proteasome inhibitors

the resistance of SCCRDEBMet and SCCIC1Met cells to a
pulse of bortezomib treatment. Resistance in these cells was
not due to a failure of bortezomib to inhibit the proteasome
(Figure 1D). Bortezomib-dependent accumulation of bulk
high molecular weight ubiquitin conjugates and the return
to baseline levels of conjugates after inhibitor removal were
indistinguishable in bortezomib-sensitive and resistant
cells (Figure 6 and Supplementary Figure 5). Proteasome
inhibition reduces the level of mono-ubiquitinated histone
H2A/H2B due to depletion of the pool of free ubiquitin
[46, 47]. Ubiquitination of these histones is involved in
regulation of transcription and DNA damage responses
[48]. The pattern of loss and recovery of histone H2A/H2B
ubiquitination was also indistinguishable in bortezomibresistant and sensitive cells (Figure 6 and Supplementary
Figure 5). Histone H2A/H2B ubiquitination was recovered
even with continuous exposure to bortezomib. There
are compensatory mechanisms which act to restore free
ubiquitin levels upon proteasome inhibition [49, 50].

We next aimed to identify mechanisms involved in
determining sensitivity/resistance to a pulse of treatment
with proteasome inhibitors. Basal levels of bulk high
molecular weight ubiquitin conjugates were elevated
in three of the eight cSCC cell lines (Supplementary
Figure 4A). There was a general increase in cSCC cells
compared to normal keratinocytes of free monomeric
ubiquitin, proteasome subunits and Ser51 phosphorylated
eiF2ɑ (Supplementary Figure 4). Increased P-eiF2ɑ is
consistent with elevated proteotoxic stress in cSCC cells
[45]. These changes may reflect a greater demand for
proteasomal degradation in the tumour cells compared to
normal keratinocytes which could contribute to the greater
sensitivity of cSCC cells to proteasome inhibition. However,
there was no clear association between these alterations and

Figure 3: Bortezomib-resistant cSCC cells can be sensitive to MLN7243. (A-C) Cells were continuously incubated with the

ubiquitin E1 inhibitor MLN7243 or treated with an 8-hour MLN7243 pulse. Cell viability (live cell number), expressed as a percentage of
carrier alone and the percentage of dead cells were assayed by real-time imaging 72 hours after drug addition. Values are the mean -/+ SEM
of 3 independent experiments. (A) Normal keratinocytes and cSCC cell lines from RDEB patients. (B) Normal keratinocytes and cSCC
cell lines from: immunocompetent (SCCIC) and transplant (SCCT) patients. (C) Relative EC50 values (μM) for reducing cell viability (live
cell number) and for promoting cell death. SCCT cells and bortezomib-resistant SCCRDEBMet and SCCIC1Met cells were sensitive to
death induced by MLN7243. (D) Cells were treated with carrier (-) or 0.1μM MLN7243 (+) for 12 hours and analysed by western blotting.
Consistent with ubiquitin E1 inhibition MLN7243 reduced high molecular weight ubiquitin conjugates and ubiquitinated histone H2A/H2B
and increased free ubiquitin.
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To identify mediators of bortezomib sensitivity
we explored the effect of knockdown of 40 candidate
regulators on the response to bortezomib (data not
shown). In bortezomib-sensitive SCCRDEB4 and
SCCIC1 cells siRNA-mediated depletion of c-MYC and
the pro-apoptotic proteins NOXA and BAK was found to
attenuate cell death in response to a pulse of bortezomib
(Figure 5A). BAK is an apoptosis effector that regulates
mitochondrial membrane permeability [51]. siRNAs
targeting other apoptosis effectors BAX and BOK did not
diminish bortezomib-dependent cell death in SCCRDEB4
cells (Supplementary Figure 6). A particular dependence
on BAK is consistent with previous observations in
mesothelioma [52]. c-MYC and NOXA are both degraded
by the proteasome [53-55]. NOXA is a transcriptional
target of c-MYC and NOXA activates BAK by binding to
the BAK repressor MCL-1 [56, 57]. In SCCRDEB4 and
SCCIC1 cells a cytotoxic concentration of bortezomib

increased c-MYC and NOXA protein expression within 8
hours of drug treatment (Figure 5B). Depletion of c-MYC
reduced the level of NOXA accumulated by bortezomib
indicating that c-MYC participates in NOXA upregulation.
This is consistent with a role of c-MYC/NOXA/BAK
acting in a common pathway to mediate cell death in
response to a pulse of bortezomib.
Basal expression of c-MYC and NOXA was
low in bortezomib-resistant normal keratinocytes and
SCCIC1Met cells and BAK levels were low in the
bortezomib-resistant SCCRDEBMet cell line (Figure
5C). Low expression of one or more of these proteins
could contribute to resistance to a pulse of bortezomib
treatment. c-MYC expression was increased in all cSCC
cell lines with elevated NOXA and knockdown of c-MYC
reduced basal NOXA expression (Figure 5B and 5C). This
indicates that c-MYC is required to maintain elevated
basal levels of NOXA. cSCC cell lines sensitive to a

Figure 4: Differences in cSCC cell line sensitivity to proteasome and ubiquitin E1 inhibitors are recapitulated in
clonogenic assays. Cells were treated with inhibitors for 72 or 8 hours, comparable to the previously used extended exposure and pulse
respectively. Cells were then maintained in drug-free medium to allow colony formation. The pattern of inhibitor sensitivity was similar
to that observed using shorter-term real-time imaging assays. SCCIC1 cells were relatively sensitive to proteasome inhibitors but resistant
to the ubiquitin E1 inhibitor MLN7243. SCCRDEB4 cells are highly sensitive to proteasome inhibitors and intermediately sensitive to
MLN7243. SCCRDEBMet cells were insensitive to an 8-hour treatment with bortezomib or ixazomib but sensitive to an 8-hour exposure
to carfilzomib. SCCRDEBMet cells were sensitive to 8 and 72 hours treatment with MLN7243.
www.oncotarget.com
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Figure 5: c-MYC-mediated NOXA upregulation is required for BAK-dependent cell death in response to a pulse of
bortezomib. (A) SCCRDEB4 and SCCIC1 cells, in which cell death is sensitive to a pulse of bortezomib, were mock-transfected (-) or
transfected with a non-targeting siRNA (Control) or siRNAs targeting c-MYC, NOXA and BAK. siRNAs 1 to 3 are complementary to
different sequences within the indicated target. Cells were exposed to an 8-hour pulse of bortezomib and cell death was assessed 24 hours
after drug addition by real-time imaging. Values are the mean -/+ SEM of at least 3 independent experiments. Knockdown of c-MYC,
NOXA, and BAK attenuated cell death in response to a short exposure to bortezomib (* P < 0.05 and *** P < 0.005 compared with control
siRNA transfected cells). (B) SCCRDEB4 and SCCIC1 cells were mock-transfected (-) or transfected with non-targeting control siRNA or
siRNAs complementary to c-MYC. Cells were treated with carrier or bortezomib (BZ) and were analysed by western blotting 8 hours after
drug addition. A cytotoxic concentration of bortezomib (0.1μM) caused c-MYC-dependent accumulation of NOXA. (C) The expression
of the indicated proteins was analysed by western blotting in the panel of cells used in this study. NHK (1) and (2) are from two different
donors. Bortezomib-resistant normal keratinocytes and SCCIC1Met cells expressed low levels of c-MYC and NOXA while bortezomibresistant SCCRDEBMet cells had low BAK levels.
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pulse of bortezomib died faster than resistant cells when
exposed to continuous bortezomib treatment (Figure 6A
and 6B). This was associated with the accumulation of
NOXA at earlier time points in cells sensitive to a pulse
of bortezomib (Figure 6B). These results suggest that
cells can be sensitive to a pulse of bortezomib because
they die rapidly in response to bortezomib treatment. High
expression of c-MYC/NOXA may confer sensitivity to a
short bortezomib exposure by priming cSCC cells for fast
bortezomib-mediated cell death.
c-MYC/NOXA/BAK also contribute to promoting
rapid cell death in response to a pulse of carfilzomib
treatment in bortezomib-sensitive cSCC cells
(Supplementary Figure 7). In carfilzomib-sensitive
but bortezomib-resistant SCCRDEBMet cells death
in response to a pulse of carfilzomib was not affected
by targeting c-MYC, NOXA or BAK (Supplementary

Figure 7A). This indicates that short-term treatment
with carfilzomib can kill these cells through another
mechanism. The engagement of an alternative mechanism
of cell death, possibly due to differences in the pattern
of proteasome inhibition, could account for the
greater sensitivity of SCCRDEBMet cells to a pulse of
carfilzomib.

UBA1 protein levels influence sensitivity to
MLN7243
To identify determinants of sensitivity to MLN7243
the protein expression of the ubiquitin E1 UBA1 was
compared in the panel of cells used in this study (Figure
7A). Two major isoforms of UBA1 are generated from
a common mRNA as a result of alternative start codon
usage [58-60]. UBA1A is localised in the nucleus and the

Figure 6: Early induction of NOXA is associated with rapid cell death in cells sensitive to a pulse of bortezomib. (A)

NHK, RDEBK and cSCC cell lines were continuously treated with 0.1 μM bortezomib. The number of dead cells was determined at the
indicated time points by real-time imaging. The results are expressed as a percentage of the maximum number of dead cells for each cell
type. Values are the mean -/+ SEM of 3 independent experiments. cSCC cell lines sensitive to a pulse of bortezomib die more rapidly
than bortezomib-resistant: normal keratinocytes, SCCRDEBMet cells and SCCIC1Met cells. (B) cSCC cell lines resistant to a pulse of
bortezomib (NHK and SCCIC1Met) and lines sensitive to a short treatment with bortezomib (SCCIC1 and SCCRDEB4) were continuously
incubated with carrier (DMSO) or 0.1 μM bortezomib (BZ) for up to 48 hours. The level of ubiquitin and ubiquitin conjugates and the
expression of the indicated proteins was analysed by western blotting. Bortezomib caused the accumulation of high molecular weight
ubiquitin conjugates in all cells irrespective of their bortezomib-susceptibility. NOXA induction and PARP and caspase 3 cleavage occurred
at earlier time points in bortezomib-sensitive cells confirming more rapid apoptosis induction.
www.oncotarget.com

20273

Oncotarget

cytoplasm. UBA1B lacks the 40 N-terminal amino acid
residues of UBA1A and is predominantly cytoplasmic.
In cSCC cells there was an inverse association between
MLN7243 sensitivity and UBA1 expression. UBA1A and
B expression was low in SCCRDEBMet and SCCT cells
which were the most MLN7243-sensitive. SCCRDEBMet
cells had the lowest levels of both UBA1 isoforms and
death in these cells was the most sensitive to a pulse of
MLN7243 (Figure 3). Conversely, UBA1A expression
was high in the SCCIC1 and SCCRDEB3 lines which
were the most MLN7243-resistant. Knockdown of
UBA1A and B in these MLN7243-resistant lines
dramatically increased sensitivity to the effects of the
E1 inhibitor on cell viability and death (Figure 7B and
7C). The level of UBA1 expression attained following
siRNA-mediated knockdown in these resistant lines and
the resulting susceptibility to MLN7243 were comparable
to those in MLN7243-sensitive SCCRDEBMet cells
(Figure 3 and 7B and 7C). Consistent with inhibition of
ubiquitin E1s, MLN7243 decreased the level of DTTsensitive UBA1 species (UBA1-ubiquitin thioesters)
along with high molecular weight ubiquitin conjugates
and ubiquitinated histones H2A/H2B while the level of
free monomeric ubiquitin was increased (Figure 7D).
These effects occurred at lower MLN7243 concentrations
in sensitive SCCRDEBMet cells than in resistant
SCCIC1 cells. UBA1 knockdown in SCCIC1 cells
reduced the concentration of MLN7243 required to
attenuate ubiquitination. In all circumstances cell death
occurred at doses of MLN7243 that diminished ubiquitin
conjugates. These results indicate that UBA1 levels are
a major determinant of the sensitivity of cSCC cells to
MLN7243 due to their influence on the concentration of
this agent required to inhibit ubiquitination. In contrast,
UBA6 protein expression was relatively uniform across
the panel of cells (Supplementary Figure 8A). Knockdown
of UBA6 in MLN7243-resistant SCCIC1 and SCCRDEB3
cells did not alter their sensitivity to the E1 inhibitor
(Supplementary Figure 8B and 8C). This indicates that
UBA6 protein levels are not a determinant of MLN7243
sensitivity in these cell lines.
Knockdown of UBA1 did not greatly alter the
pattern of bulk high molecular weight ubiquitin conjugates
in cSCC cells, even in the SCCRDEBMet line which
expresses the lowest endogenous levels of the E1 (Figure
7 and Supplementary Figure 9). In addition, knockdown of
UBA6 alone and in combination with UBA1 did not alter
high molecular weight ubiquitination in SCCRDEBMet
cells (Supplementary Figure 9B). This suggests that
ubiquitin E1s are not normally rate-limiting for the
formation of these ubiquitin conjugates in the cSCC
cell lines tested and that in these cells E1 activity needs
to be strongly inhibited in order for ubiquitination to be
attenuated. Levels of ubiquitinated histone H2A/H2B
were reduced by knockdown of UBA1 (Figure 7B and 7D
and Supplementary Figure 9). A decrease in ubiquitinated
www.oncotarget.com

histone H2A/H2B could provide a sensitive readout of
UBA1 suppression.

DISCUSSION
We compared the effects in normal keratinocytes
and cSCC cell lines of a long and short treatment with
proteasome inhibitors and the ubiquitin E1 inhibitor
MLN7243. We show that a pulse of proteasome inhibitor
exposure results in greater selectivity for killing cSCC
cells than a more extended exposure. In sensitive cSCC
cell lines a pulse of bortezomib treatment gives the highest
level of selectivity compared to normal keratinocytes but
some cSCC cell lines are bortezomib-resistant. These
bortezomib-resistant tumour cells can be sensitive to
MLN7243. Carfilzomib is more generally cSCC selective
than bortezomib or MLN7243. We provide evidence
that c-MYC, NOXA and BAK are determinants of
susceptibility to a pulse of proteasome inhibition and that
low UBA1 expression confers susceptibility to MLN7243.
This study indicates that the cSCC selectivity of
a pulse of proteasome inhibitor exposure is related to a
differential dependency for survival of sensitive cSCC
cells and normal keratinocytes on the proteolytic activities
of the proteasome. For example, killing of the most
bortezomib-sensitive cSCC cell lines by a short treatment
with bortezomib occurs at inhibitor concentrations that
markedly attenuate the chymotrypsin and caspase-like
activities but only modestly inhibit the trypsin-like activity.
In normal keratinocytes death is associated with inhibition
of all three activities at high bortezomib concentrations.
This suggests that the window of selectivity for cSCC
cells compared to normal keratinocytes can be determined
by the specificity of inhibitors for the activities of the
proteasome. For instance, a small molecule which inhibits
the chymotrypsin and caspase-like activities without
substantially inhibiting the trypsin-like activity may show
even greater selectivity for sensitive cSCC cells than
bortezomib. These results are consistent with the previous
finding that inhibition of different individual proteolytic
activities and combinations of proteolytic activities of
the proteasome results in distinct degrees of interference
with protein degradation [15, 16]. The extent to which
the proteolytic activities are inhibited could consequently
influence which cellular pathways are affected and the
strength of their modulation.
We observed that concentrations of bortezomib and
carfilzomib that kill cSCC cell lines have divergent effects
on the proteolytic activities of the proteasome. Variations
in the extent to which cellular pathways are affected due
to these differences in proteasome inhibition may underlie
the greater cSCC selectivity of continuous exposure to
carfilzomib and the ability of a pulse of carfilzomib to kill
cSCC cells resistant to a short treatment with bortezomib.
Consistent with this, our study indicates that a pulse of
carfilzomib can induce cell death by different mechanisms
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Oncotarget

Figure 7: Low UBA1 protein expression is a determinant of sensitivity to MLN7243. (A) The expression of UBA1 in the panel

of cells used in this study was analysed by western blotting. This was carried out using a primary antibody that detects both major UBA1
isoforms: UBA1A (upper band) and UBA1B (lower band) and an antibody that is specific for UBA1A. UBA1A and B expression was lowest
in MLN7243-sensitive SCCRDEBMet and SCCT cells while UBA1A expression was high in MLN7243-resistant SCCRDEB3 and SCCIC1
cells. (B) MLN7243-resistant SCCIC1 and SCCRDEB3 cells were mock-transfected (-) or transfected with the indicated siRNAs. UBA1
siRNAs 1 to 4 are complementary to different UBA1 sequences. Ubiquitin E1 expression and the pattern of ubiquitination were analysed
by western blotting 72 hours after transfection. The UBA1 siRNAs efficiently depleted UBA1 while having no effect on the level of UBA6
or bulk high molecular weight ubiquitin conjugates. (C) MLN7243-resistant SCCIC1 and SCCRDEB3 cells were transfected with siRNAs
targeting UBA1. Cell viability (live cell number) expressed as a percentage of carrier alone for each siRNA and cell death were analysed
by real-time imaging 72 hours after the initiation of continuous incubation with MLN7243. Values are the mean -/+ SEM of 3 experiments.
Knockdown of UBA1 dramatically increased sensitivity to MLN7243. (D) MLN7243-sensitive SCCRDEBMet cells and MLN7243-resistant
SCCIC1 cells were transfected with the indicated siRNAs. Samples were analysed by western blotting for UBA1 and ubiquitin 12 hours
after initiating continuous incubation with MLN7243. More slowly migrating UBA1-ubiquitin thioesters were preserved by running samples
in the absence of reducing agent (-DTT). MLN7243 decreased UBA1 thioesters. Cells with low UBA1 expression were more sensitive to
MLN7243-induced decreases in high molecular weight ubiquitin conjugates and ubiquitinated histone H2A/H2B.
www.oncotarget.com
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in bortezomib-resistant and bortezomib-sensitive cells.
Differences in the mechanisms through which distinct
proteasome inhibitors kill cells have been observed
previously [61].
c-MYC, NOXA and BAK promote cell death in
response to an extended exposure to bortezomib in a
number of cancer types [43, 52, 54, 55, 57, 62, 63]. This
study confirms that this pathway can play an important role
in mediating cell death induced by a pulse of bortezomib.
In addition, we observed that this pathway can also
participate in killing bortezomib-sensitive cSCC lines by
a pulse of carfilzomib. c-MYC and NOXA levels are low
in normal keratinocytes which provides a mechanism for
tumour selectivity. Furthermore, cSCC cell lines resistant
to a pulse of bortezomib have low basal levels of c-MYC
and NOXA or BAK. Low basal expression of these
proteins is consequently a potential marker for bortezomib
resistance in cSCCs. In support of this, a decrease in
c-MYC and NOXA expression is involved in the acquired
resistance of mesothelioma cells to bortezomib [52].
Encouragingly, c-MYC protein expression is upregulated
in 75 to 85% of cSCCs and BAK protein is expressed in
95% of cSCCs [64-67]. Our results indicate that cells are
sensitive to a pulse of bortezomib because they undergo
more rapid bortezomib-induced death than resistant
cells. Early c-MYC-dependent accumulation of the BAK
activator NOXA contributes to promoting quicker cell
death in bortezomib-sensitive cells. Both c-MYC and
NOXA are degraded by the proteasome and c-MYC
promotes NOXA transcription. Upregulation of basal
NOXA mRNA expression by elevated c-MYC could
contribute to fast protein accumulation upon inhibition
of the proteasomal degradation of NOXA. Proteasome
inhibition also increases c-MYC transcriptional activity
towards the NOXA gene [52, 57, 68].
The pattern of sensitivity of cSCC cells to ubiquitin
E1 inhibition is different from proteasome inhibitors. The
two cSCC cell lines most resistant to a pulse of bortezomib
are among the most sensitive to MLN7243-induced cell
death. We observed that low expression of both UBA1A
and B isoforms is associated with MLN7243 sensitivity
and high expression of UBA1A with MLN7243 resistance.
Furthermore, knockdown of UBA1A and B confers
MLN7243 sensitivity to resistant cSCC cells. MLN7243induced cell death is associated with a reduction in the
level of ubiquitin conjugates. A lower concentration of
MLN7243 is required to diminish ubiquitination in cSCC
cells with low UBA1 expression. UBA1 protein levels
may thus provide a marker for tumour sensitivity to
MLN7243. It would be of great interest to determine the
mechanisms responsible for the observed differences in
UBA1A and B expression. A better understanding of how
levels of UBA1 isoforms are regulated could lead to the
development of therapeutic interventions that modulate
their expression. This may provide a means to enhance
tumour sensitivity or increase the resistance of normal
www.oncotarget.com

cells to MLN7243. UBA1 and UBA6 are both inhibited
by MLN7243. While our study supports a pre-eminent
role of UBA1 in determining the sensitivity of cSCC
cells to MLN7243 under some circumstances suppression
of UBA6 could contribute to the anti-tumour activity of
this inhibitor. UBA6 can play a non-redundant role in
maintaining cell viability [10, 69].
A high degree of E1 suppression is required to
reduce bulk high molecular weight ubiquitin conjugates
in the cSCC cell lines examined. This indicates that
the ubiquitin E1s are not normally rate-limiting for
these ubiquitination events. This is consistent with
previous studies [38]. UBA1 is a highly active enzyme
and it is able to charge excess amounts of E2s with
ubiquitin [70]. There are examples of cancer-derived
cells, including acute and chronic myeloid leukaemia
cell lines where UBA1 is closer to rate-limiting for
ubiquitination [37]. These cancers may be highly
sensitive to MLN7243.
This study indicates that there is therapeutic
potential for proteasome and UBA1 inhibition for cSCC.
Future work could initially be aimed at developing direct
delivery of inhibitors to tumours. This would overcome
limitations of systemic delivery and allow optimal
exposure of cSCCs. Effective directly-delivered therapy
would be of benefit to cSCC patients and it would inform
systemic therapy for treating cSCC and other solid
tumours.

MATERIALS AND METHODS
Cell culture
Normal keratinocytes (NHK and RDEBK) and
cSCC cell lines were isolated and maintained as described
[71, 72]. Cells were routinely grown at 37oC and 5%
CO2 in a humidified atmosphere in keratinocyte medium
containing 10% serum and growth factors [72]. Normal
keratinocytes were grown in the presence of a mitotically
inactivated 3T3 fibroblast feeder layer. RDEBK were
expanded using the ROCK inhibitor Y-27632 (1254:
Tocris Bioscience, Bristol, UK) which was removed 48
hours prior to the initiation of experiments [73]. cSCC
cell lines were cultured in the absences of feeder cells.
SCCRDEBMet (SCCRDEB70) and RDEBK cells were
a gift from Dr Andrew P. South (Thomas Jefferson
University). The tissue from which these cells were
derived was provided by Jemima E. Mellerio (King’s
College London) and Julio C. Salas-Alanís (DEBRA
Mexico). SCCT (MET1) and SCCTMet (MET4) cell lines
were described previously [74]. SCCIC1/SCCIC1Met
and SCCT/SCCTMet cell lines are derived from paired
primary tumours and their metastases. For experiments,
cells were plated in the absence of feeders in keratinocyte
medium containing 10% serum and growth factors with
no added EGF.
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Inhibitor treatment

direct lysis into SDS electrophoresis sample buffer: 100
mM Tris pH 6.8, 4% SDS, 20% glycerol, 20 mM EDTA,
0.014% bromophenol blue. Western blotting was carried
out as described previously [75]. Membranes probed for
ubiquitin were boiled for 30 minutes in de-ionized water
prior to blocking to increase epitope exposure.

Inhibitors were dissolved in DMSO (20 to 50 mM
stocks). Unless otherwise indicated cells were treated with
inhibitors 16 to 24 hours after plating. Compounds used
in this study were: bortezomib (B-1408: LC Laboratories
Woburn, MA, USA), carfilzomib (S2853: Selleckchem,
Houston, TX, USA), ixazomib (S2180: Selleckchem) and
MLN7243 (CT-M7243: Chemietek, Indianapolis, IN, USA).

Abbreviations
Bortezomib (BZ), cutaneous squamous cell
carcinoma (cSCC), mono-ubiquitinated histone H2A/
H2B (uH2A/B), normal human keratinocytes (NHK),
recessive dystrophic epidermolysis bullosa (RDEB),
recessive dystrophic epidermolysis bullosa keratinocytes
(RDEBK), squamous cell carcinoma immunocompetent
(SCCIC), squamous cell carcinoma recessive dystrophic
epidermolysis bullosa (SCCRDEB), squamous cell
carcinoma transplant (SCCT) and ubiquitin-like (UBL).

siRNA transfection
Dharmacon ON-TARGETplus modified siRNAs
(Thermo Fisher Scientific, Waltham, MA, USA) were
used in this work and are listed in Supplementary Figure
10. Reverse transfection with synthetic siRNA duplexes
(10 nM) was carried out using Invitrogen Lipofectamine
RNAiMAX transfection reagent (13778150: Thermo
Fisher Scientific) according to the manufacturer’s
instructions. Inhibitors were added 48 hours after
transfection to ensure target knockdown before initiating
drug treatment.
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